Mustang Bio (MBIO) AI Stock Analysis

• Market Cap: $5.30M
• Dividend Yield: N/A
• Average Volume (3M): 94.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: 98.58%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 6,732,092
• 10 Day Avg. Volume: 88,215
• 30 Day Avg. Volume: 94,141
• PEG Ratio: 0.30
• Price to Book (P/B): 5.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.15
• Enterprise Value/Market Cap: -2.26
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 291.75
• Enterprise Value/Ebitda: 5.60
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $0.75 ▼(-31.19% Downside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is mainly driven by improved financial trajectory (narrowing losses and reduced cash burn) and a low-debt balance sheet, offset by continued lack of revenue and negative free cash flow. Technicals remain weak with the stock trading below major moving averages, and valuation signals are constrained by persistent losses and no dividend support.

Positive Factors

Improving cash burn trend

Free cash flow has materially improved across multiple years, shrinking absolute cash burn from very large negatives toward single-digit millions. This durable downward trend reduces near-term fundraising frequency, extends operational runway, and increases optionality for advancing trials or pursuing partnerships without immediate capital stress.

Negative Factors

No revenue / pre-commercial profile

As a pre-commercial biotech, Mustang lacks recurring product revenue, leaving limited visibility into sustainable earnings or margin profiles. Long-term viability depends on successful commercialization or durable partnerships; without revenues, the firm remains structurally dependent on financing events to bridge development to market.

Mustang Bio Business Overview & Revenue Model

Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on g...

Read more

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on g...

How the Company Makes Money

Mustang Bio is a clinical-stage company and, as such, does not have a broadly established, recurring product-revenue base from commercialized therapies. The company has historically funded operations primarily through capital raising (e.g., equity...

Read more

Mustang Bio is a clinical-stage company and, as such, does not have a broadly established, recurring product-revenue base from commercialized therapies. The company has historically funded operations primarily through capital raising (e.g., equity...

Mustang Bio Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-41.00K	0.00	-2.23M	-3.03M	-2.31M
EBITDA	-2.39M	-14.92M	-48.06M	-71.14M	-64.05M
Net Income	-1.92M	-15.75M	-51.60M	-77.53M	-66.37M
Balance Sheet
Total Assets	17.59M	9.31M	17.74M	92.42M	125.17M
Cash, Cash Equivalents and Short-Term Investments	17.27M	6.84M	6.23M	75.66M	109.62M
Total Debt	0.00	878.00K	2.50M	31.38M	2.03M
Total Liabilities	8.06M	13.18M	17.62M	46.15M	12.77M
Stockholders Equity	9.53M	-3.87M	123.00K	46.27M	112.40M
Cash Flow
Free Cash Flow	-5.26M	-11.41M	-49.59M	-68.14M	-59.03M
Operating Cash Flow	-5.26M	-11.41M	-49.48M	-65.07M	-53.67M
Investing Cash Flow	1.17M	0.00	5.89M	-2.95M	-5.37M
Financing Cash Flow	14.53M	11.27M	-26.08M	34.06M	70.85M

Mustang Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBIO, the sentiment is Negative. The current price of 1.09 is above the 20-day moving average (MA) of 0.79, above the 50-day MA of 0.87, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 31.01 is Neutral, neither overbought nor oversold. The STOCH value of 27.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBIO.

Mustang Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBIO	50 Neutral	$5.30M	-25.06	-418.83%	―	―	98.58%
XTLB	―	$6.24M	-5.30	―	―	―	65.45%
BOLT	47 Neutral	$9.43M	-0.31	-97.58%	―	-46.88%	34.83%
ACXP	44 Neutral	$7.45M	-0.47	-291.07%	―	―	61.10%
SLXN	41 Neutral	$3.50M	-0.21	-529.06%	―	―	91.47%
LYRA	39 Underperform	$1.15M	-1.65	1211.14%	―	-59.21%	68.97%